Company has incorporated guidance from FDA on key elements of its Phase 3 program to support…
Continue ReadingTag: immuno-oncology
Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms
Analysis shows clinically meaningful benefit from symptoms, global patient-reported and real-world assessments
Continue ReadingRitter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy
LOS ANGELES, CA -- (Marketwired) -- 02/13/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or…
Continue Reading